



Recent Development of Anticancer Agents

Guest Editor:

Dr. Alfonso Zambon

Dipartimento di Scienze
Chimiche e Geologiche,
Università degli Studi di Modena
e Reggio Emilia, 41125 Modena,
Italy

Deadline for manuscript
submissions:

closed (10 September 2022)

Message from the Guest Editor

Recent fundamental breakthroughs in the understanding of the molecular mechanisms regulating the development and spread of tumours and the immune response to cancer have led to an increasing number and variety of cancer therapies. The options available to cancer patients now include immunotherapy and targeted therapy alongside classical endocrine, radiation and chemo therapies. There is, however, a pressing medical need linked to the intrinsic or acquired resistance to cancer drugs. Drug resistance is still responsible for most relapses of cancer, and is one of the major causes of death of the disease. Current cancer research is often aimed at the development of therapeutic agents for cancer treatment that will also be able to overcome drug resistance.

This Special Issue will focus on original research articles and reviews on the drug discovery and development process translating basic research in new anticancer therapies, with a particular focus on the elucidation of the molecular mechanisms involved in neoplastic processes and the development of small molecule inhibitors for cancer treatment.

Keywords:

small molecule inhibitors
cancer therapy
cancer drug resistance
drug discovery





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Giulio Nicola Cerullo

Dipartimento di Fisica,
Politecnico di Milano, Piazza L.
da Vinci 32, 20133 Milano, Italy

Message from the Editor-in-Chief

As the world of science becomes ever more specialized, researchers may lose themselves in the deep forest of the ever increasing number of subfields being created. This open access journal Applied Sciences has been started to link these subfields, so researchers can cut through the forest and see the surrounding, or quite distant fields and subfields to help develop his/her own research even further with the aid of this multi-dimensional network.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), Inspec, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Engineering, Multidisciplinary*) / CiteScore - Q1 (*General Engineering*)

Contact Us

Applied Sciences Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/applsci
applsci@mdpi.com
X@Applsci